Leverage Data to Improve Cell Collection

Your manufacturing process is heavily dependent on the quality of input material. Whether you are starting with a clinical evaluation of CAR T-cell therapy or scaling from phase 1 to phase 2, the input material obtained from the patient matters. Each patient is different, and collections can vary. Control over what can be controlled becomes even more important.

Our Services:

• Spectra Optia Cell Collection Data Analysis: Simple or multiple data analyses, comprehensive analysis from pre-procedure data to therapy outcomes, optimization recommendations
• Spectra Optia Predictive Algorithm: Review of collection data, customized calculation of whole blood processing steps, statistical summary analysis

Materials

• White Paper: Basics of Cell Collection – Introduction and Fundamentals for HSCT and C> Industry
• Case Study: Cell Collection Data Analysis Improves Performance and Reduces Collection Days
• Success Story: Hospital Increases Average Stem Cell Yield by 32%
• Success Story: Improved Cell Collection Target Yields from 47% to 92%